Eurolyser Diagnostics - Premium Laboratory Equipment

Troponin I test

Cardiac troponin I

About the parameter

Cardiac troponin I is expressed in cardiac muscle tissue by a single isoform with a molecular weight of 23876 Da and consists of 209 amino acid residues. For more than 15 years, troponin I has been known in literature as a reliable marker of cardiac muscle tissue injury and is considered to be more sensitive and significantly more specific in diagnosis of the myocardial infarction than the “golden marker” of the last decades – CK­MB.

Published literature states that serum levels of cardiac enzymes and isoenzymes are essential to the diagnosis or exclusion of myocardial damage and that cardiac troponin I is specific for cardiac tissue and is detected in the serum only if myocardial injury has occurred. These reports state that troponin I determination allows early identification and stratification of patients with chest pain suggestive of ischaemia, allows identification of patients that present 48 hours to 6 days after infarction, and identifies patients with false positive elevations in CK­MB1­6.



The cardiac troponin I assay is based on a latex-enhanced immunoturbidimetric assay. Cardiac troponin I in the sample binds to the specific anti troponin I antibodies, which are coated on latex particles, and causes agglutination.

The degree of the turbidity caused by agglutination can be measured optically and is proportional to the amount of troponin I in the sample.

Measurement range

1.00 ng/ml – 10.00 ng/ml

Reference range
The reference range is recommended as < 1.50 ng/ml.

Test duration

The test takes approximately 10 minutes.

Package insert

More details can be found in the package insert.

Please note: All package inserts provided on this website are intended for information purposes only! Always process all tests, controls and calibrators strictly according to the package insert provided with the kit.

Appropriate instruments



smart 700/340

smart 700/546


Assay evaluation

Find the evaluation study for the Eurolyser Troponin I assay here: Evaluation Eurolyser Troponin I

Please note: depending on the time of the market launch of an assay, the respective assay evaluation was carried out using either a Eurolyser smart instrument or a Eurolyser CUBE instrument.

Since the measurement method is the same in both instruments (their photometric units are identical in construction), as was proved in this comparison study, all testkit evaluations provided on this website are valid for either instrument!

Additional information

Article numbers

ST 0230     Troponin I test kit (containing 6 tests)
ST 2300     Troponin I control kit (decision level)

Decreased patient charges with point-of-care troponin I testing

Result of a medical study

A study demonstrates the clinical effectiveness and cost superiority of point-of-care testing for assisting clinicians with diagnostic and risk assessment of acute coronary syndrome (ACS) patients.

“The need to rapidly evaluate patients presenting to emergency departments and cardiology services for ruling in and ruling out acute myocardial infarction (AMI) is widely recognized as a clinical challenge. We determined the impact of incorporating point-of-care (POC) cardiac troponin I (cTnI) testing into a cardiology service regarding assay turn around time (TAT), patient length of stay (LOS), financial matrixes and patient outcomes compared to central laboratory cTnI testing.”

The full study can be found here: Apple FS, Chung AY, Kogut ME, Bubany S, Muramami, MM. Decreased patient charges following implementation of point-of-care cardiac troponin monitoring in acute coronary syndrome patients in a community hospital cardiology unit. Clinica Chimica Acta 2006; 370, 1-2: 191-95

Eurolyser News

18. August 2020

SDMA: A new veterinary assay for evaluation of chronic kidney diseases...
»

17. August 2020

Phenobarbital: A next generation epilepsy monitoring assay...
»

10. December 2019

Launch of bidirectional connectivity: a feature for CUBE series instruments...
»

5. December 2019

Eurolyser is now ISO 13485:2016 certified...
»